Downregulation of GRIM-19 promotes growth and migration of human glioma cells

Cancer Science

Volumn 102, Issue 11, 2011, Pages 1991-1999

  Zhang, Yanmin ^a   Hao, Hongbo ^b   Zhao, Shidou ^a   Liu, Qian ^a   Yuan, Qiuhuan ^a   Ni, Shilei ^c   Wang, Fuwu ^a   Liu, Shangming ^a   Wang, Liyan ^a   Hao, Aijun ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN; PROTEIN GRIM 19; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE; GENE EXPRESSION REGULATION; GLIOMA CELL; GRIM 19 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BRAIN; BRAIN NEOPLASMS; CELL DIVISION; CELL MOVEMENT; CYCLOOXYGENASE 2; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; GLIOMA; HUMANS; NADH, NADPH OXIDOREDUCTASES; NEOPLASM PROTEINS; NERVE TISSUE PROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RECOMBINANT FUSION PROTEINS; RNA INTERFERENCE; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CHOP; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 80054982787     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02059.x     Document Type: Article

References (49)

1. Figarella-Branger D, Colin C, Coulibaly B et al. Histological and molecular classification of gliomas. Rev Neurol (Paris) 2008; 164: 505-15.
2. Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
3. Kleihues P, Soylemezoglu F, Schauble B, Scheithauer BW, Burger PC. Histopathology, classification, and grading of gliomas. Glia 1995; 15: 211-21.
4. Ohgaki H, Dessen P, Jourde B et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004; 64: 6892-9.
5. Grimmer MR, Weiss WA. Childhood tumors of the nervous system as disorders of normal development. Curr Opin Pediatr 2006; 18: 634-8.
6. Read TA, Hegedus B, Wechsler-Reya R, Gutmann DH. The neurobiology of neurooncology. Ann Neurol 2006; 60: 3-11.
7. Goodrich LV, Scott MP. Hedgehog and patched in neural development and disease. Neuron 1998; 21: 1243-57.
8. Hirvonen O, Lakkakorpi J, Aaltonen V et al. Developmental regulation of NF1 tumor suppressor gene in human peripheral nerve. J Neurocytol 1998; 27: 939-52.
9. Zhu Y, Harada T, Liu L et al. Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development 2005; 132: 5577-88.
10. Angell JE, Lindner DJ, Shapiro PS, Hofmann ER, Kalvakolanu DV. Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-beta and retinoic acid combination, using a genetic approach. J Biol Chem 2000; 275: 33416-26.
11. Hofmann ER, Boyanapalli M, Lindner DJ et al. Thioredoxin reductase mediates cell death effects of the combination of beta interferon and retinoic acid. Mol Cell Biol 1998; 18: 6493-504.
12. Lufei C, Ma J, Huang G et al. GRIM-19, a death-regulatory gene product, suppresses Stat3 activity via functional interaction. EMBO J 2003; 22: 1325-35.
13. Lu H, Cao X. GRIM-19 is essential for maintenance of mitochondrial membrane potential. Mol Biol Cell 2008; 19: 1893-902.
14. Kalvakolanu DV, Nallar SC, Kalakonda S. Cytokine-induced tumor suppressors: a GRIM story. Cytokine 2010; 52: 128-42.
15. Huang G, Lu H, Hao A et al. GRIM-19, a cell death regulatory protein, is essential for assembly and function of mitochondrial complex I. Mol Cell Biol 2004; 24: 8447-56.
16. Alchanati I, Nallar SC, Sun P et al. A proteomic analysis reveals the loss of expression of the cell death regulatory gene GRIM-19 in human renal cell carcinomas. Oncogene 2006; 25: 7138-47.
17. Fusco A, Viglietto G, Santoro M. Point mutation in GRIM-19: a new genetic lesion in Hurthle cell thyroid carcinomas. Br J Cancer 2005; 92: 1817-18.
18. Zhou Y, Li M, Wei Y et al. Down-regulation of GRIM-19 expression is associated with hyperactivation of STAT3-induced gene expression and tumor growth in human cervical cancers. J Interferon Cytokine Res 2009; 29: 695-703.
19. Du Z, Jia D, Liu S et al. Oct4 is expressed in human gliomas and promotes colony formation in glioma cells. Glia 2009; 57: 724-33.
20. Mehrabian Z, Chandrasekaran K, Kalakonda S, Kristian T, Fiskum G, Kalvakolanu DV. The IFN-beta and retinoic acid-induced cell death regulator GRIM-19 is upregulated during focal cerebral ischemia. J Interferon Cytokine Res 2007; 27: 383-92.
21. Wang H, Lathia JD, Wu Q et al. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 2009; 27: 2393-404.
22. Marino S. Medulloblastoma: developmental mechanisms out of control. Trends Mol Med 2005; 11: 17-22.
23. Wechsler-Reya R, Scott MP. The developmental biology of brain tumors. Annu Rev Neurosci 2001; 24: 385-428.
24. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998; 19: 348-55.
25. Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R. Epidermal growth factor receptor - mediated signal transduction in the development and therapy of gliomas. Clin Cancer Res 2006; 12: 7261-70.
26. Chidambaram NV, Angell JE, Ling W, Hofmann ER, Kalvakolanu DV. Chromosomal localization of human GRIM-19, a novel IFN-beta and retinoic acid-activated regulator of cell death. J Interferon Cytokine Res 2000; 20: 661-5.
27. Ritland SR, Ganju V, Jenkins RB. Region-specific loss of heterozygosity on chromosome 19 is related to the morphologic type of human glioma. Genes Chromosom Cancer 1995; 12: 277-82.
28. Dehan P, Kustermans G, Guenin S, Horion J, Boniver J, Delvenne P. DNA methylation and cancer diagnosis: new methods and applications. Expert Rev Mol Diagn 2009; 9: 651-7.
29. Sun P, Nallar SC, Raha A et al. GRIM-19 and p16INK4a synergistically regulate cell cycle progression and E2F1-responsive gene expression. J Biol Chem 2010; 285: 27545-52.
30. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
31. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-62.
32. Zhang J, Yang J, Roy SK et al. The cell death regulator GRIM-19 is an inhibitor of signal transducer and activator of transcription 3. Proc Natl Acad Sci USA 2003; 100: 9342-7.
33. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002; 8: 945-54.
34. Gao SP, Bromberg JF. Touched and moved by STAT3. Sci STKE 2006; 2006: pe30.
35. Brantley EC, Benveniste EN. Signal transducer and activator of transcription-3: a molecular hub for signaling pathways in gliomas. Mol Cancer Res 2008; 6: 675-84.
36. Haura EB, Turkson J, Jove R. Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2005; 2: 315-24.
37. Shirai K, Suzuki Y, Oka K et al. Nuclear survivin expression predicts poorer prognosis in glioblastoma. J Neurooncol 2009; 91: 353-8.
38. Lytle RA, Jiang Z, Zheng X, Higashikubo R, Rich KM. Retinamide-induced apoptosis in glioblastomas is associated with down-regulation of Bcl-xL and Bcl-2 proteins. J Neurooncol 2005; 74: 225-32.
39. Ding Q, Grammer JR, Nelson MA, Guan JL, Stewart JE Jr, Gladson CL. p27Kip1 and cyclin D1 are necessary for focal adhesion kinase regulation of cell cycle progression in glioblastoma cells propagated in vitro and in vivo in the scid mouse brain. J Biol Chem 2005; 280: 6802-15.
40. Chen H, Huang Q, Dong J, Zhai DZ, Wang AD, Lan Q. Overexpression of CDC2/CyclinB1 in gliomas, and CDC2 depletion inhibits proliferation of human glioma cells in vitro and in vivo. BMC Cancer 2008; 8: 29.
41. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 2005; 7: 134-53.
42. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci 2007; 8: 610-22.
43. Kim SH, Hwang CI, Juhnn YS, Lee JH, Park WY, Song YS. GADD153 mediates celecoxib-induced apoptosis in cervical cancer cells. Carcinogenesis 2007; 28: 223-31.
44. Onguru O, Casey MB, Kajita S, Nakamura N, Lloyd RV. Cyclooxygenase-2 and thromboxane synthase in non-endocrine and endocrine tumors: a review. Endocr Pathol 2005; 16: 253-77.
45. Joki T, Heese O, Nikas DC et al. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res 2000; 60: 4926-31.
46. Stetler-Stevenson WG, Hewitt R, Corcoran M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol 1996; 7: 147-54.
47. MacDougall JR, Matrisian LM. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev 1995; 14: 351-62.
48. Nakada M, Okada Y, Yamashita J. The role of matrix metalloproteinases in glioma invasion. Front Biosci 2003; 8: e261-9.
49. Raithatha SA, Muzik H, Muzik H et al. Localization of gelatinase-A and gelatinase-B mRNA and protein in human gliomas. Neuro Oncol 2000; 2: 145-50.